Relmada Therapeutics has appointed Max Kates, MD, a leading urologic oncologist from Johns Hopkins and chair of the large, ongoing BRIDGE phase 3 trial in non–muscle invasive bladder cancer, to its clinical advisory board to guide NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel. The company plans to initiate phase 3 testing of NDV-01 in the first half of 2026, positioning the program for potential late-decade readouts and, if successful, a play at standardizing a widely used off-label regimen.
The strategic signal is clear: Relmada aims to convert the community-driven, off-label “gem/doce” practice into a proprietary, evidence-based, and reimbursable product with real-world practicality. In an NMIBC landscape reshaped by BCG shortages, rising cystectomy avoidance goals, and new entrants spanning gene therapy and immuno-cytokine combinations, the race is on to define what “bladder-sparing standard” will mean operationally and economically in everyday urology. Bringing in the physician most associated with the pivotal head-to-head evaluation of gem/doce versus BCG suggests Relmada intends to design a phase 3 program that aligns with how care is actually delivered in high-volume practices.
Why this matters now is as much about delivery and economics as biology. NDV-01 is engineered for 10-day bladder retention with a soft-matrix release after a brief in-office instillation that does not require anesthesia or specialized equipment. If the product can reliably enhance exposure while minimizing systemic toxicity, it offers a workflow-friendly alternative at the site of care where most NMIBC is managed. For payers, the calculation will hinge on durable response, time to recurrence, and cystectomy avoidance, balanced against the reality that NDV-01 must justify premium pricing versus generic gemcitabine and docetaxel. For patients and HCPs, convenience and reduced procedure burden could be decisive if outcomes prove comparable or superior to current options.
The competitive context is tightening. Since 2020, checkpoint inhibition has provided a lifeline for BCG-unresponsive patients, gene therapy added a bladder-sparing option, and, in 2024, immuno-cytokine approaches widened the menu. Meanwhile, device-enabled intravesical delivery, notably gemcitabine-releasing platforms, underscores a broader trend: turning known agents into high-value assets through controlled, durable exposure and simplified administration. NDV-01’s patents through 2038, coupled with a pragmatic install profile, mirror this “reformat the generic” playbook that many biotechs are leveraging to de-risk biology while competing on usability, consistency, and payer-aligned outcomes.
For Commercial and Medical Affairs leaders, the execution agenda is plain. Trial design must capture endpoints that resonate beyond response rates—health-economic measures, resource utilization, and quality of life in community settings will be essential to inform coverage policy. Early engagement with urology networks, ambulatory sites, and buy-and-bill mechanics will determine whether NDV-01 can secure favorable coding and formulary positioning. Real-world evidence programs should be ready on day one to validate durability, adherence to intravesical protocols, and reductions in costly downstream interventions.
The core question is whether Relmada can translate widespread off-label behavior into a proprietary standard before rival platforms cement guideline slots and payer contracts. If NDV-01’s phase 3 replicates meaningful durability with minimal operational friction, it could redefine bladder-sparing care as a site-of-care solution rather than a hospital-based procedure. If it cannot, innovators with earlier regulatory momentum may lock in the category. The next move will be telling: does Relmada pursue partnerships with urology-focused commercial organizations to accelerate market shaping ahead of 2026, or go it alone and risk being late to a rapidly professionalizing NMIBC market?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
